Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
SVB Financial Group and its subsidiaries were involved in over $1.4 billion in total venture financing raised from 2010 to 2022 for drug development
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)